AU674936B2 - Recombinant Epstein-Barr viral capsid antigen useful in diagnostic method - Google Patents
Recombinant Epstein-Barr viral capsid antigen useful in diagnostic method Download PDFInfo
- Publication number
- AU674936B2 AU674936B2 AU62693/94A AU6269394A AU674936B2 AU 674936 B2 AU674936 B2 AU 674936B2 AU 62693/94 A AU62693/94 A AU 62693/94A AU 6269394 A AU6269394 A AU 6269394A AU 674936 B2 AU674936 B2 AU 674936B2
- Authority
- AU
- Australia
- Prior art keywords
- ebv
- protein
- recombinant
- document
- international
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000002405 diagnostic procedure Methods 0.000 title description 3
- 108010026292 Epstein-Barr viral capsid antigen Proteins 0.000 title description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 83
- 102000004169 proteins and genes Human genes 0.000 claims description 80
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 39
- 230000014509 gene expression Effects 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 25
- 241000701447 unidentified baculovirus Species 0.000 claims description 25
- 206010015108 Epstein-Barr virus infection Diseases 0.000 claims description 15
- 238000002965 ELISA Methods 0.000 claims description 12
- 238000003018 immunoassay Methods 0.000 claims description 11
- 238000003556 assay Methods 0.000 claims description 10
- 238000010166 immunofluorescence Methods 0.000 claims description 10
- 230000035945 sensitivity Effects 0.000 claims description 9
- 238000003745 diagnosis Methods 0.000 claims description 5
- 230000000405 serological effect Effects 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 210000004027 cell Anatomy 0.000 description 35
- 239000000427 antigen Substances 0.000 description 22
- 108091007433 antigens Proteins 0.000 description 22
- 102000036639 antigens Human genes 0.000 description 22
- 241000588724 Escherichia coli Species 0.000 description 19
- 239000012634 fragment Substances 0.000 description 16
- 239000013598 vector Substances 0.000 description 14
- 230000003612 virological effect Effects 0.000 description 14
- 210000000234 capsid Anatomy 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 239000006180 TBST buffer Substances 0.000 description 11
- 241000700605 Viruses Species 0.000 description 11
- 201000006747 infectious mononucleosis Diseases 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 241000238631 Hexapoda Species 0.000 description 8
- 230000027455 binding Effects 0.000 description 8
- 239000013612 plasmid Substances 0.000 description 8
- 229920001184 polypeptide Polymers 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 108091081024 Start codon Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 101710182846 Polyhedrin Proteins 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 241000272168 Laridae Species 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000001042 affinity chromatography Methods 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 4
- QRXMUCSWCMTJGU-UHFFFAOYSA-L (5-bromo-4-chloro-1h-indol-3-yl) phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP([O-])(=O)[O-])=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-L 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102100029727 Enteropeptidase Human genes 0.000 description 3
- 108010013369 Enteropeptidase Proteins 0.000 description 3
- 108010008655 Epstein-Barr Virus Nuclear Antigens Proteins 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000013861 fat-free Nutrition 0.000 description 3
- 108091005608 glycosylated proteins Proteins 0.000 description 3
- 102000035122 glycosylated proteins Human genes 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012761 co-transfection Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 230000002101 lytic effect Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 108090000565 Capsid Proteins Proteins 0.000 description 1
- 102100023321 Ceruloplasmin Human genes 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000701867 Enterobacteria phage T7 Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000958664 Homo sapiens Nucleus accumbens-associated protein 1 Proteins 0.000 description 1
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 208000030289 Lymphoproliferative disease Diseases 0.000 description 1
- 101710179282 Major DNA-binding protein Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 108010036939 Occlusion Body Matrix Proteins Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000012769 bulk production Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 208000011902 cervical lymphadenopathy Diseases 0.000 description 1
- 239000012539 chromatography resin Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000013578 denaturing buffer Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- KAKKHKRHCKCAGH-UHFFFAOYSA-L disodium;(4-nitrophenyl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[O-][N+](=O)C1=CC=C(OP([O-])([O-])=O)C=C1 KAKKHKRHCKCAGH-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 101150029683 gB gene Proteins 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 244000039328 opportunistic pathogen Species 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000011309 routine diagnosis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
- C07K4/02—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- C12N2710/14141—Use of virus, viral particle or viral elements as a vector
- C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2195193A | 1993-02-23 | 1993-02-23 | |
| US021951 | 1993-02-23 | ||
| PCT/US1994/001775 WO1994019495A1 (en) | 1993-02-23 | 1994-02-23 | Recombinant epstein-barr viral capsid antigen useful in diagnostic method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6269394A AU6269394A (en) | 1994-09-14 |
| AU674936B2 true AU674936B2 (en) | 1997-01-16 |
Family
ID=21807030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU62693/94A Ceased AU674936B2 (en) | 1993-02-23 | 1994-02-23 | Recombinant Epstein-Barr viral capsid antigen useful in diagnostic method |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0687308A4 (de) |
| JP (1) | JPH08507681A (de) |
| KR (1) | KR960701218A (de) |
| AU (1) | AU674936B2 (de) |
| CA (1) | CA2150691A1 (de) |
| WO (1) | WO1994019495A1 (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130115207A1 (en) * | 2010-04-09 | 2013-05-09 | The General Hospital Corporation | Methods for the treatment of autoimmune diseases |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU609779B2 (en) * | 1987-02-26 | 1991-05-09 | Behringwerke Aktiengesellschaft | Immunogenic fusion proteins which contain epstein-barr virus protein |
-
1994
- 1994-02-23 WO PCT/US1994/001775 patent/WO1994019495A1/en not_active Application Discontinuation
- 1994-02-23 EP EP94910134A patent/EP0687308A4/de not_active Withdrawn
- 1994-02-23 AU AU62693/94A patent/AU674936B2/en not_active Ceased
- 1994-02-23 KR KR1019950703301A patent/KR960701218A/ko not_active Application Discontinuation
- 1994-02-23 CA CA002150691A patent/CA2150691A1/en not_active Abandoned
- 1994-02-23 JP JP6519171A patent/JPH08507681A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU609779B2 (en) * | 1987-02-26 | 1991-05-09 | Behringwerke Aktiengesellschaft | Immunogenic fusion proteins which contain epstein-barr virus protein |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1994019495A1 (en) | 1994-09-01 |
| CA2150691A1 (en) | 1994-09-01 |
| JPH08507681A (ja) | 1996-08-20 |
| AU6269394A (en) | 1994-09-14 |
| EP0687308A4 (de) | 1997-07-09 |
| KR960701218A (ko) | 1996-02-24 |
| EP0687308A1 (de) | 1995-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mach et al. | Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73) | |
| Greijer et al. | Molecular fine-specificity analysis of antibody responses to human cytomegalovirus and design of novel synthetic-peptide-based serodiagnostic assays | |
| US6013433A (en) | Baculovirus expression vectors and recombinant antigens for detecting type-specific antibodies to herpes simplex virus | |
| Gorgievski-Hrisoho et al. | Serodiagnosis of infectious mononucleosis by using recombinant Epstein-Barr virus antigens and enzyme-linked immunosorbent assay technology | |
| Lang et al. | Cross-reactivity of Epstein-Barr virus-specific immunoglobulin M antibodies with cytomegalovirus antigens containing glycine homopolymers | |
| CA2131874C (en) | Diagnostic reagents for the detection of antibodies to ebv | |
| Landini et al. | Human cytomegalovirus structural proteins: immune reaction against pp150 synthetic peptides | |
| JP4368406B2 (ja) | エプスタイン・バールウイルスのペプチド及びこれらのペプチドに対する抗体 | |
| Landini et al. | Serum antibodies to individual cytomegalovirus structural polypeptides in renal transplant recipients during viral infection | |
| US5965354A (en) | Herpes simplex virus diagnostics | |
| Plachter et al. | Detection of cytomegalovirus antibodies by an enzyme-linked immunosorbent assay using recombinant polypeptides of the large phosphorylated tegument protein pp150 | |
| US6143865A (en) | Epstein-Barr virus peptides and antibodies against these peptides | |
| EP0730155A1 (de) | Verfahren zur prüfung von antiphospholipid-antikörper und testsatz dazu | |
| Serio et al. | Two 21-kilodalton components of the Epstein-Barr virus capsid antigen complex and their relationship to ZEBRA-associated protein p21 (ZAP21) | |
| Hinderer et al. | Serodiagnosis of Epstein-Barr virus infection by using recombinant viral capsid antigen fragments and autologous gene fusion | |
| AU674936B2 (en) | Recombinant Epstein-Barr viral capsid antigen useful in diagnostic method | |
| Stefan et al. | Development of recombinant diagnostic reagents based on pp85 (U14) and p86 (U11) proteins to detect the human immune response to human herpesvirus 7 infection | |
| Pohl-Koppe et al. | Detection of human coronavirus 229E-specific antibodies using recombinant fusion proteins | |
| Inoue et al. | Use of enzyme-linked immunosorbent assays with chimeric fusion proteins to titrate antibodies against Epstein-Barr virus nuclear antigen 1 | |
| EP0536319B1 (de) | Test zum nachweis und/oder quantifizierung einer antikörperreaktion eines säugetiers gegen epstein-barr-virus-membranantigen | |
| Franti et al. | Immune reactivity of human sera to the glycoprotein B of human herpesvirus 7 | |
| IE912291A1 (en) | Antigen | |
| Geertsen et al. | Development of a recombinant enzyme-linked immunosorbent assay for detection of antibodies against Epstein-Barr virus nuclear antigens 2A and 2B | |
| Gutiérrez et al. | A recombinant protein-based enzyme immunoassay for IgM antibody to human cytomegalovirus | |
| Gan et al. | Distribution of Epstein‐Barr virus antigenic sites on the carboxyl terminal end of ribonucleotide reductase against nasopharyngeal carcinoma serum antibodies using an immunoabsorption method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |